GlassScriptPhysician profile
Benedict L Gierl
NPI 1649397969
$9,254.66
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,318 · 2020: $1,430 · 2021: $2,701 · 2022: $2,241 · 2023: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,437.36 | 2019-2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $1,236.35 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,119.91 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $865.70 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $839.82 | 2019-2023 | Austedo |
| Urovant Sciences INC | $822.96 | 2021-2022 | |
| Allergan, INC. | $667.32 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $595.19 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $542.10 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $403.91 | 2019-2023 | Nuedexta |
| Abbvie INC. | $312.12 | 2021-2022 | |
| Lundbeck LLC | $219.49 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $137.35 | 2021-2022 | |
| Alkermes, INC. | $25.00 | 2022 | |
| Sumitomo Pharma America, INC. | $15.15 | 2023 | Gemtesa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $14.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Gierl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.